Adverts

Open Access Articles- Top Results for Selurampanel

Selurampanel

</th></tr>
Selurampanel
File:Selurampanel.svg
Systematic (IUPAC) name
N-[7-Isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methanesulfonamide
Clinical data
Identifiers
912574-69-7
None
PubChem CID 45381907
ChemSpider 32698379
Chemical data
Formula C16H19N5O4S
377.418 g/mol

Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.[4]

See also

References

  1. Faught, Edward (2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs 23 (1): 107–113. ISSN 1354-3784. doi:10.1517/13543784.2014.848854. 
  2. Belcastro, Vincenzo; Verrotti, Alberto (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy". pp. 183–199. doi:10.1007/978-3-319-12283-0_10. 
  3. Hanada, Takahisa (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. ISSN 1178-699X. doi:10.2147/JRLCR.S51475. 
  4. Gomez-Mancilla B, Brand R, Jürgens TP et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks". Cephalalgia 34 (2): 103–13. PMID 23963355. doi:10.1177/0333102413499648. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.